Abstract:RNA virus infections are composed of a diverse mix of viral genomes that arise from low fidelity in replication within cells. The interactions between "defective" and full-length viral genomes have been shown to shape pathogenesis, leading to intense research into employing these to develop novel antivirals. In particular, Influenza A defective viral genomes (DVGs) have been associated with milder clinical outcomes. Yet, the full potential of DVGs as broad-spectrum antivirals remains untapped due to the unknown mechanisms of their de novo production. Much of the research into the factors affecting defective viral genome production has focused on the virus, while the role of the host has been neglected. We recently showed that altering host cell metabolism away from pro-growth pathways using alpelisib increased the production of Influenza A defective viral genomes. To uncover other drugs that could induce infections to create more DVGs, we subjected active influenza infections of the two circulating human subtypes (A/H1N1 & A/H3N2) to a screen of metabolites, metabolic signaling molecules, and cyanobacteria-derived biologics, after which we quantified the defective viral genomes (specifically deletion-containing viral genomes, DelVGs) and total viral genomes using third generation long-read sequencing. Here we show that metabolites and signaling molecules of host cell central carbon metabolism can significantly alter DelVG production early in Influenza A infection. Adenosine, emerged as a potent inducer of defective viral genomes, significantly amplifying DelVG production across both subtypes. Insulin had similar effects, albeit subtype-specific, predominantly enhancing polymerase segment DVGs in TX12 infections. Tricarboxylic Acid (TCA) cycle inhibitors 4-octyl itaconate and UK5099, along with the purine analog favipiravir, increased total viral genome production across subtypes. Cyanobacterial extracts primarily affected DVG and total viral genome production in TX12, with a specific, almost complete shutdown of influenza antigenic segments. These results underscore the influence of host metabolic pathways on DVG production and suggest new avenues for antiviral intervention, including PI3K-AKT and Ras-MAPK signaling pathways, TCA cycle metabolism, purine-pyrimidine metabolism, polymerase inhibition, and cyanotherapeutic approaches. More broadly, our findings suggest that the social interactions observed between defective and full-length viral genomes, depend not only on the viral actors, but can be altered by the stage provided by the host. Our study advances our fundamental understanding of DVG production mechanisms and highlights the potential of targeting host metabolism to develop broad-spectrum influenza therapeutics.

Triggering Degradation of Host Cellular Proteins for Robust Propagation of Influenza Viruses

NMI Facilitates Influenza A Virus Infection by Promoting Degradation of IRF7 Through TRIM21.

Unveiling the role of host kinases at different steps of influenza A virus life cycle

How Influenza A Virus NS1 Deals with the Ubiquitin System to Evade Innate Immunity

Evolution of Influenza A Virus by Mutation and Re-Assortment

Targeting the Ubiquitin Proteasome System to Combat Influenza A Virus: Hijacking the Cleanup Crew

Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy

Influenza A defective viral genome production is altered by metabolites, metabolic signaling molecules, and cyanobacteria extracts

Proteomic Analysis at the Subcellular Level for Host Targets Against Influenza A Virus (H1N1)

Influenza A virus-induced apoptosis and virus propagation

The nucleoprotein of influenza A virus inhibits the innate immune response by inducing mitophagy

Virus versus host: influenza A virus circumvents the immune responses

Host Innate Antiviral Response to Influenza A Virus Infection: From Viral Sensing to Antagonism and Escape

Deficiency of HIF-1α enhances influenza A virus replication by promoting autophagy in alveolar type II epithelial cells

Protein turnover regulation is critical for influenza A virus infection

Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents

Cell-to-Cell Variation in Defective Virus Expression and Effects on Host Responses During Influenza Virus Infection

Role of Influenza A virus protein NS1 in regulating host nuclear body ND10 complex formation and its involvement in establishment of viral pathogenesis

Influenza A viruses induce tunnelling nanotube-like structures through the onset of apoptosis

Escaping mechanism from innate immunity mediated clearance by high pathogenic influenza virus during infection

Influenza A Virus-Encoded NS1 Virulence Factor Protein Inhibits Innate Immune Response by Targeting IKK.